Home
Trade
SpotFuturesStocks
LendBP
Tools
WatchlistsScreenerGraphsCalendar

More

​$​0123456789​.01234567890123456789​

Today

$0.00

+0.00%

Mkt Cap

Volume

Next Earnings

ChartFinancialsNewsAbout
Adagene Inc. American Depositary Shares

Adagene Inc. American Depositary Shares

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

adagene.com

Ticker

ADAG

Market cap

$146.83M

IPO Date

Feb 9, 2021

Employees

128

Balances
Positions
Open Orders
Borrows
TWAP
Fill History
Order History
Position History
Funding History
All
Crypto
Stocks
Asset

Brokerage services in your region are provided through Trek Brokerage Services Limited, a company licensed by the Anjouan Offshore Finance Authority, acting as Intermediary Broker pursuant to the Backpack Securities Brokerage Services Terms of Service. Please see our Brokerage Services Terms and Conditions available here. Investing in stocks involves risks, including the total loss of your investment. The value of investments can go down as well as up, and past performance is not a reliable indicator of future results. You should consider seeking independent financial or legal advice before making any investment decision. It is your responsibility to ensure that your use of this platform and any investments made comply with the laws and regulations of your jurisdiction.